Greenwoods Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Greenwoods Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-83,031	Closed	-$1.13M	–	27
2018 Q4	$1.13M	Sell	83,031 -268,500	-76%	-$4.99M	0.11%	22
2018 Q3	$10.1M	Buy	351,531 +104,000	+42%	+$3.03M	0.98%	8
2018 Q2	$6.77M	Hold	247,531	–	–	0.61%	12
2018 Q1	$5.22M	Buy	247,531 +123,500	+100%	+$3.04M	0.43%	15
2017 Q4	$2.38M	Buy	+124,031	New	+$2.86M	0.2%	18

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Greenwoods Asset Management's NTLA Position: Q1 2019 in Review

Greenwoods Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2019, closing a stake of 83,031 shares — an estimated $1.13M sold.

Greenwoods Asset Management first reported a position in NTLA in Q4 2017 and held it in 5 quarters. The position peaked at $10.1M in Q3 2018. 148 funds tracked by Wall St. Rank hold NTLA as of Q1 2019.

Greenwoods Asset Management reported no remaining Intellia Therapeutics position as of Q1 2019 after selling out during the quarter.
Greenwoods Asset Management sold 83,031 Intellia Therapeutics shares in Q1 2019, an estimated $1.13M.
Greenwoods Asset Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 5 quarters.
Greenwoods Asset Management's Intellia Therapeutics position peaked at $10.1M in Q3 2018.
148 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2019.

Based on Greenwoods Asset Management's 13F filing for Q1 2019, filed 14 May 2019.